

# FREDUN PHARMACEUTICALS LIMITED

*Compassionate Healthcare*



CIN No : L24239MH1987PLC043662

Date: 19<sup>th</sup> July, 2023

To

**BSE Ltd.**

Listing Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street - Fort,  
Mumbai – 400 001

**Ref.: BSE Scrip Code - 539730**

Dear Sir/ Madam,

**Sub: Intimation under Regulation 30 and Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 on appointment of Additional Director in the Category of an Independent Director of the Company and Resignation of Independent Director**

Pursuant to Regulation 30 and Schedule III of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that based on the recommendation of the Nomination & Remuneration Committee of the Board, the Board of Directors of the Company in their meeting held today i.e. Wednesday 19<sup>th</sup> July, 2023 have approved the following:

- Appointment of Ms. Niharika Agarwal (DIN: 10192397) as Additional Director in the Category of Independent Director on the Board of the Company for a term of 5 years subject to the approval by the members in the ensuing Annual General Meeting.
- Resignation of Dr. Chandrakant Shah (DIN: 02843653) as Independent Director with effect from 19th July, 2023.

The relevant details as per the requirement of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIRJCFD/CMD/4/2015 dated September 09, 2015, are given in the enclosed "**Annexure-I**".


Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: [business@fredungroup.com](mailto:business@fredungroup.com) Web: [www.fredungroup.com](http://www.fredungroup.com)



**“Annexure I”**

**Disclosure required pursuant to Regulation 30 of the Listing Regulations read with Para A of Schedule III to the Listing Regulations read with the SEBI Circular having reference no. CIR/CFD/CMD/4/2015 dated September 9 2015, with regard to change in Directors and Key Managerial Personnel is given herein under:**

Appointment of Ms. Niharika Agarwal (DIN: 10192397) and Resignation of Dr. Chandrakant Shah (DIN: 02843653).

Sr. No.	Disclosure requirements	Details	
		Ms. Niharika Agarwal	Dr. Chandrakant Shah
1.	Reason for Change viz. Appointment, Resignation, Removal, Death or Otherwise	Appointment of Ms. Niharika Agarwal as an Additional Director (Non-Executive, Independent Director) of the Company.	Resignation of Mr. Chandrakant as Independent Director of the Company due to age and medical conditions
2.	Date of Appointment/ Cessation & Term of appointment	Appointed w.e.f. 19 <sup>th</sup> July, 2023 in the category of Non-Executive Independent Director for a period of five years' subject to approval of Shareholders.	Effective from closing of business hours on 19 <sup>th</sup> July, 2023

**Registered Office:** Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

**Phone No.:** 91-22- 4031 8111 **Fax:** 91-22-4031 8133

**Factory:** 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

**Phone No.:** +917045957828, +917045957829, +917045957830, +917045956857

**E-Mail:** [business@fredungroup.com](mailto:business@fredungroup.com) **Web:** [www.fredungroup.com](http://www.fredungroup.com)



CIN No: L24239MH1987PLC043662

3.	Brief Profile	<p>Ms. Nikarika Agarwal has completed her Master's in Biotechnology from Pennsylvania State University in August 2018. She began her career as a scientific student employee at GlaxoSmithKline in January 2018 and later continued there as a Senior Scientist from October 2018 to August, 2022.</p> <p>She also successfully completed Harvard Business School's Credential of Readiness (CORE) program with Honors in October 2018 and Fluent Control Training from Tecan in March, 2019.</p> <p>Few of the laboratory procedures she is skilled in include Aseptic culture techniques, Automation, Cloning, Fluorescence, Immunodetection of proteins, Nucleic Acid purification, Protein expression and purification, PCR, UV/Vis, Capillary Electrophoresis, High-throughput platform development.</p> <p>Ms. Niharika Agarwal has completed Mini-MBA: BioPharma Innovation in December 2020 and is currently pursuing Master of Business and Science in Drug Discovery and Development from Rutgers University.</p>	Not Applicable
4.	Disclosure of relationships	She is not related to any of the Directors on the Board.	Not Applicable
5.	Other Directorship and Category	Not Applicable	Not Applicable
6.	Membership Committee	Not Applicable	Not Applicable

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: [business@fredungroup.com](mailto:business@fredungroup.com) Web: [www.fredungroup.com](http://www.fredungroup.com)



# FREDUN PHARMACEUTICALS LIMITED

*Compassionate Healthcare*



CIN No: L24239MH1987PLC043662

Further, the Company has received confirmation from Dr. Chandrakant Shah that there are no material reasons for his resignation. The resignation letter dated 19<sup>th</sup> July, 2023 is enclosed herewith.

Yours faithfully,

For Fredun Pharmaceuticals Limited

Fredun Medhora  
Managing Director  
DIN: 01745348


Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.

Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133

Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.

Phone No.: +917045957828, +917045957829, +917045957830, +917045956857

E-Mail: [business@fredungroup.com](mailto:business@fredungroup.com) Web: [www.fredungroup.com](http://www.fredungroup.com)



**Date: 19<sup>th</sup> July, 2023**

**To,**  
**The Board of Directors**  
**Fredun Pharmaceuticals Limited**  
11th Floor, Tower A, Urmi Estate 95,  
Ganpatrao Kadam Marg, Lower Parel (W)  
Delisle Road, Mumbai-400013.

**Sub: Retirement from the position of Independent Director**

Dear Sir/ Ma'am,

I hereby tender my retirement from the office of Independent Director of Fredun Pharmaceuticals Limited effective from the closing of business hours on 19<sup>th</sup> July, 2023. Further, I declare that I am retiring because of my age and medical conditions.

In accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with Clause 78 of Part A of schedule III of Listing Regulations, I hereby confirm that there due to my age of 85 years and medical conditions I retire.

I wish to express my gratitude towards the Board of the Company for giving me an opportunity to serve on the Board. I wish the Company all the success in the future.

I further confirm that,

1. I do not have any claim whatsoever against Fredun Pharmaceuticals Limited whether for loss of office, accrued remuneration or otherwise; and
2. Fredun Pharmaceuticals Limited has no claims whatsoever against me.

I request the Board to kindly accept my retirement and relieve me from my position in the Company. Please make arrangements to file necessary forms with the concerned Registrar of Company and intimations to the stock exchanges.

**Thanking you.**

**Yours Faithfully,**



**Chandrakant Kanchanlal Shah**  
**DIN: 02843653**